{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:27:48Z","timestamp":1776400068649,"version":"3.51.2"},"reference-count":42,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174360"],"award-info":[{"award-number":["82174360"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["CI2021A01702"],"award-info":[{"award-number":["CI2021A01702"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific and technological innovation project of China Academy of Chinese Medical Sciences","award":["82174360"],"award-info":[{"award-number":["82174360"]}]},{"name":"Scientific and technological innovation project of China Academy of Chinese Medical Sciences","award":["CI2021A01702"],"award-info":[{"award-number":["CI2021A01702"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Thrombosis is a common complication of myeloproliferative neoplasm (MPN), and it is a major cause of disability and death. With the development of next-generation gene-sequencing technology, the relationship between non-driver mutations and thrombotic risk factors has also attracted considerable attention. To analyze the risk factors of thrombosis in patients with essential thrombocythemia (ET) and polycythemia vera (PV), we retrospectively analyzed the clinical data of 125 MPN patients (75 ET and 50 PV) and performed a multivariate analysis of the risk factors of thrombosis using a Cox proportional risk model. Among the 125 patients, 35 (28.0%) had thrombotic events, and the incidence of thrombotic events was 21.3% and 38.0% in ET and PV patients, respectively. In ET patients, the multivariate analysis showed that a TET2 mutation and history of remote thrombosis were independent risk factors for thrombosis in ET patients, with an HR of 4.1 (95% CI: 1.40\u201312.01; p = 0.01) for TET2 mutation and 6.89 (95% CI: 1.45\u201332.68; p = 0.015) for a history of remote thrombosis. In PV patients, the multivariate analysis presented the neutrophil-to-lymphocyte ratio (NLR) (HR: 4.77, 95% CI: 1.33\u201317.16; p = 0.017) and a history of remote thrombosis (HR: 1.67, 95% CI: 1.03\u20131.32; p = 0.014) as independent risk factors for thrombosis, with no significant change in the risk of thrombosis in patients with TET2 mutations. A further analysis of the clinical characteristics and coagulation occurring in ET patients with a TET2 mutation revealed that the values of age and D-dimer were significantly higher and antithrombin III was significantly lower in TET2-mutated ET patients compared to TET2-unmutated patients. In summary, TET2 mutation may be more valuable in predicting thrombosis in ET patients than in PV patients. ET patients with a TET2 mutation are older and present differences in coagulation compared to TET2-unmutated patients.<\/jats:p>","DOI":"10.3390\/jcm11226615","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T10:53:52Z","timestamp":1667904832000},"page":"6615","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["TET2 Mutation May Be More Valuable in Predicting Thrombosis in ET Patients Compared to PV Patients: A Preliminary Report"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3016-2345","authenticated-orcid":false,"given":"Ziqing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"},{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"},{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-3101","authenticated-orcid":false,"given":"Erpeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"},{"name":"Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"},{"name":"Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"},{"name":"Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"},{"name":"Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00277-020-04028-z","article-title":"Ruxolitinib-based combinations in the treatment of myelofibrosis: Worth looking forward to","volume":"99","author":"Li","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.2147\/OTT.S287944","article-title":"Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data","volume":"13","author":"Loscocco","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","article-title":"Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis","volume":"12","author":"Martin","year":"2017","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Loscocco, G., Coltro, G., Guglielmelli, P., and Vannucchi, A. (2021). Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 10.","DOI":"10.3390\/cells10081962"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41375-021-01410-2","article-title":"RBC distribution width predicts thrombosis risk in polycythemia vera","volume":"36","author":"Liu","year":"2022","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2020008","DOI":"10.4084\/mjhid.2020.008","article-title":"Cardiovascular risk in essential thrombocythemia and polycythemia vera: Thrombotic risk and survival","volume":"12","author":"Accurso","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Segura-D\u00edaz, A., Stuckey, R., Florido, Y., Gonz\u00e1lez-Mart\u00edn, J.M., L\u00f3pez-Rodr\u00edguez, J.F., S\u00e1nchez-Sosa, S., Gonz\u00e1lez-P\u00e9rez, E., S\u00e1ez Perdomo, M.N., Perera, M.d.M., and de la Iglesia, S. (2020). Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A\/TET2\/ASXL1 Mutations. Cancers, 12.","DOI":"10.3390\/cancers12040934"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1038\/bcj.2017.17","article-title":"Prognostic impact of bone marrow fibrosis in polycythemia vera: Validation of the IWG-MRT study and additional observations","volume":"7","author":"Barraco","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00277-020-04387-7","article-title":"Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: A meta-analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_16","first-page":"4149","article-title":"ASXL1 mutations in Chinese patients with essential thrombocythemia","volume":"15","author":"Nie","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments","volume":"93","author":"Za","year":"2008","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u20132012","volume":"174","author":"Srour","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11899-021-00630-8","article-title":"Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms","volume":"16","author":"Reeves","year":"2021","journal-title":"Curr. Hematol. Malign. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.14735\/amko2019109","article-title":"High Level of Circulating Microparticles in Patients with BCR\/ ABL Negative Myeloproliferative Neoplasm\u2013A Pilot Study","volume":"32","author":"Aswad","year":"2019","journal-title":"Klin. Onkol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: A systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00277-017-2956-3","article-title":"Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: The immature platelet and reticulocyte fractions","volume":"96","author":"Strati","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ajcp\/aqw222","article-title":"Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis","volume":"147","author":"Song","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-014-0048-6","article-title":"The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"7","author":"Wu","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kim, H.-R., Choi, H.-J., Kim, Y.-K., Kim, H.-J., Shin, J.-H., Suh, S.-P., Ryang, D.-W., and Shin, M.-G. (2013). Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0052518"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lee, J.-M., Lee, H., Eom, K.-S., Lee, S.-E., Kim, M., and Kim, Y. (2021). Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051033"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00639-z","article-title":"Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases","volume":"12","author":"Gangat","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.26423","article-title":"Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia","volume":"97","author":"Farrukh","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12185-020-02898-7","article-title":"Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera","volume":"112","author":"Holik","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1080\/10428194.2020.1731503","article-title":"Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera","volume":"61","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-021-04431-0","article-title":"Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera","volume":"100","author":"Holik","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","article-title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: A single center experience in 587 patients","volume":"7","author":"Cerquozzi","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-022-00625-5","article-title":"Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera","volume":"12","author":"Carobbio","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.21570","article-title":"The number of people with sickle cell disease in the United States: National and state estimates","volume":"85","author":"Brousseau","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/BS9.0000000000000055","article-title":"Loss of Tet2 affects platelet function but not coagulation in mice","volume":"2","author":"Wang","year":"2020","journal-title":"Blood Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1038\/s41467-022-30669-x","article-title":"P-selectin mobility undergoes a sol-gel transition as it diffuses from exocytosis sites into the cell membrane","volume":"13","author":"Hellen","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6615\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:36Z","timestamp":1760145156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":42,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11226615"],"URL":"https:\/\/doi.org\/10.3390\/jcm11226615","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]}}}